生化基因 BIIB 深 沪
等待开盘 01-29 09:30:00 美东时间
174.83
+0.710
+0.41%
华盛通- 最 高175.06
- 今 开173.63
- 成交量 130.47万股
- 最 低 170.85
- 昨 收 174.12
- 总市值 257.00亿
- 52周最高 190.20
- 市盈率 静 15.63
- 换手率 0.89%
- 52周最低 110.035
- 委 比 -83.55%
- 总股本 1.47亿
- 历史最高 468.55
- 量 比 1.19
- 振 幅 2.42%
- 历史最低 61.605
- 每 手 1
- 风险率 18.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Expert Outlook: Biogen Through The Eyes Of 11 Analysts
Ratings for Biogen (NASDAQ:BIIB) were provided by 11 analysts in the past three...
01-28 05:01
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
Eisai and Biogen have submitted a supplemental application for LEQEMBI IQLIK, seeking FDA approval for a weekly starting dose, offering at-home injection options for early Alzheimer’s disease. This subcutaneous autoinjector aims to provide flexibility and reduce healthcare burdens while maintaining clinical benefits demonstrated in trials.
01-25 23:30
Looking Into Biogen Inc's Recent Short Interest
Biogen Inc's (NYSE:BIIB) short interest as a percent of float has fallen 32.24%...
01-24 03:00
美股异动丨渤健盘前涨超1% 高盛看好Leqembi与研发管线支撑增收增利结构性变革
格隆汇1月15日｜渤健公司(BIIB.US)盘前涨1.26%，报171.45美元。消息面上，高盛在与渤健管理层会面后，给予其“买入”评级，目标价225美元。高盛...
01-15 17:47
百健(BIIB.US)押注家用阿尔茨海默病药物 称将成对抗礼来(LLY.US)的“制胜筹码”
百健公司(BIIB.US)首席执行官克里斯·维巴赫近日表示，其与卫材合作开发的Leqembi家用注射剂型将成为公司对抗竞争对手礼来(LLY.US)同类疗法的“关键优势”。
01-14 21:24
Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share
Biogen (BIIB) expects its Q4 results to include acquired in-process research and development, upfront and milestone expenses of around $222M on a pre-tax basis. The estimated charge is expected to imp...
01-14 19:41
Biogen Granted European Commission's Marketing Authorization Approval For High Dose Regimen Of SPINRAZA
Biogen Inc. (NASDAQ:BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for
01-13 00:06
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
<p>Biogen announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). The high dose regimen includes 50 mg and 28 mg doses, designed for a more rapid loading phase and four-month maintenance injections. The approval is supported by data from the DEVOTE study, showing significant improvements in motor function for treatment-naïve ...
01-12 16:05
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
